In addition to this, triazolopyrimidine derivatives exhibit acetylcholinesterase (AChE) inhibitory properties, an important factor necessary for the treatment of Alzheimer’s disease (AD) [1,2,3,11,12,13]. Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.